Member Contact: Shane Duncan
Position: General Manager, Commercial
Industry: Biotech & Pharmaceuticals
Cann Group Limited (ASX:CAN) is an industry leader, with a focus on the breeding and cultivation of cannabis, and the manufacture of Medicinal Cannabis Products for sale and use within Australia and export markets. Through the hard work of a talented and dedicated team, Cann is working to provide the highest quality Medicinal Cannabis Products to patients to treat a range of medical conditions. With licensed research, cultivation and manufacture facilities in Victoria, Cann Group is working to provide 100% Australian grown Medicinal Cannabis Products for patients; with the company's vision is to become a leading developer and supplier of Medicinal Cannabis Products. Cann Group Limited was the first company in Australia to be granted a cannabis cultivation licence, and has subsequently been issued a manufacturing licence.
Cann Group has developed a number of strategic partnerships both in Australia and abroad, including Aurora Cannabis Inc; one of the world's largest cannabis producers. We also have a partnership with IDT Australia for manufacturing support for our cannabis-based product formulations and we are currently working with IDT to commission their extraction and other manufacturing facilities for cGMP compliance for medicinal cannabis production. As one of the largest companies in the medicinal cannabis sector, we are involved in the whole process of delivering medicinal cannabis to the Australian community, from plant to patient. As the Chairman of Medicinal Cannabis Industry Australia (MCIA), our CEO Peter Crock has an intimate working knowledge of the sector; with Cann’s business relating to the BioMelbourne Network due to its involvement in agribiotech, research (both on plants and in patients), GMP manufacturing and regulatory issues surrounding medicinal cannabis.